RhumbLine Advisers’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

RhumbLine Advisers’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-147,167	Closed	-$982K	–	4286
2023 Q3	$982K	Buy	147,167 +2,101	+1%	+$17.5K	﹤0.01%	2223
2023 Q2	$1.31M	Buy	145,066 +31,742	+28%	+$280K	﹤0.01%	2152
2023 Q1	$824K	Buy	113,324 +12,344	+12%	+$91.6K	﹤0.01%	2216
2022 Q4	$736K	Buy	100,980 +8,122	+9%	+$60.3K	﹤0.01%	2288
2022 Q3	$718K	Buy	92,858 +6,580	+8%	+$55.9K	﹤0.01%	2326
2022 Q2	$588K	Buy	+86,278	New	+$660K	﹤0.01%	2406

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

RhumbLine Advisers's PNT Position: Q4 2023 in Review

RhumbLine Advisers sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 147,167 shares — an estimated $982K sold.

RhumbLine Advisers first reported a position in PNT in Q2 2022 and held it in 6 quarters. The position peaked at $1.31M in Q2 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

RhumbLine Advisers reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
RhumbLine Advisers sold 147,167 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $982K.
RhumbLine Advisers first reported a position in POINT Biopharma Global Inc. Common Stock in Q2 2022 and held it in 6 quarters.
RhumbLine Advisers's POINT Biopharma Global Inc. Common Stock position peaked at $1.31M in Q2 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on RhumbLine Advisers's 13F filing for Q4 2023, filed 8 Feb 2024.